Advertisement

Relationships between squamous cell carcinoma antigen and cytokeratin 19 fragment values and renal function in oral cancer patients

  • K. Obata
    Correspondence
    Correspondence to: Department of Oral and Maxillofacial Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kitaku, Okayama 700-8558, Japan.
    Affiliations
    Department of Oral and Maxillofacial Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
    Search for articles by this author
  • H. Yutori
    Affiliations
    Department of Oral and Maxillofacial Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
    Search for articles by this author
  • K. Yoshida
    Affiliations
    Department of Oral and Maxillofacial Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
    Search for articles by this author
  • Y. Sakamoto
    Affiliations
    Department of Oral and Maxillofacial Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
    Search for articles by this author
  • K. Ono
    Affiliations
    Department of Oral and Maxillofacial Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
    Search for articles by this author
  • S. Ibaragi
    Affiliations
    Department of Oral and Maxillofacial Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
    Search for articles by this author
Published:September 09, 2022DOI:https://doi.org/10.1016/j.ijom.2022.08.019

      Abstract

      Squamous cell carcinoma antigen (SCC-Ag) and cytokeratin 19 fragment (CYFRA) are used to screen and monitor oral cancer patients. However, recent studies have reported that tumour markers become elevated as renal function decreases, regardless of tumour progression. A retrospective study was performed of 423 oral cancer patients who underwent blood testing for these tumour markers and other blood analytes during a 10-year period. The values of SCC-Ag and CYFRA increased significantly with decreasing renal function (P < 0.01), and the values were abnormal at a median 2.6 ng/ml for SCC-Ag and 4.7 ng/ml for CYFRA in the group with estimated glomerular filtration rate (eGFR) values of< 30 ml/min/1.73 m2. The factors that were related to the variation in tumour markers were albumin and creatinine. The cut-off values of eGFR were 59.7 ml/min/1.73 m2 for SCC-Ag and 63.6 ml/min/1.73 m2 for CYFRA, and the cut-off age when the tumour markers might rise due to the effect of renal function were 72 years for SCC-Ag and 73 years for CYFRA. In conclusion, decreased renal function should be taken into account when evaluating tumour markers in oral cancer. In addition, tumour markers are likely to be overestimated in patients over the age of 72–73 years.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to International Journal of Oral and Maxillofacial Surgery
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Johnson D.E.
        • Burtness B.
        • Leemans C.R.
        • Lui V.W.Y.
        • Bauman J.E.
        • Grandis J.R.
        Head and neck squamous cell carcinoma.
        Nat Rev Dis Primers. 2020; 692https://doi.org/10.1038/s41572-020-00224-3
        • Sung H.
        • Ferlay J.
        • Siegel R.L.
        • Laversanne M.
        • Soerjomataram I.
        • Jemal A.
        • Bray F.
        Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
        CA Cancer J Clin. 2021; 71: 209-249https://doi.org/10.3322/caac.21660
        • Ferlay J.
        • Colombet M.
        • Soerjomataram I.
        • Mathers C.
        • Parkin D.M.
        • Piñeros M.
        • Znaor A.
        • Bray F.
        Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods.
        Int J Cancer. 2019; 144: 1941-1953https://doi.org/10.1002/ijc.31937
        • Yang K.
        • Chen D.
        Diagnostic values of serum tumor markers in oral/oropharyngeal squamous cell carcinoma.
        OncoTargets Ther. 2016; 9: 3381-3386
        • Barak V.
        • Meirovitz A.
        • Leibovici V.
        • Rachmut J.
        • Peretz T.
        • Eliashar R.
        • Gross M.
        The diagnostic and prognostic value of tumor markers (CEA, SCC, CYFRA 21-1, TPS) in head and neck cancer patients.
        Anticancer Res. 2015; 35: 5519-5524
        • Jones H.B.
        On a new substance occurring in the urine of a patient with mollities ossium.
        Phil Trans R Soc. 1848; 138: 55-62https://doi.org/10.1098/rstl.1848.0003
        • Coppolino G.
        • Bolignano D.
        • Rivoli L.
        • Mazza G.
        • Presta P.
        • Fuiano G.
        Tumour markers and kidney function: a systematic review.
        Biomed Res Int. 2014; 2014647541https://doi.org/10.1155/2014/647541
        • Amiri F.S.
        Serum tumor markers in chronic kidney disease: as clinical tool in diagnosis, treatment and prognosis of cancers.
        Ren Fail. 2016; 38: 530-544https://doi.org/10.3109/0886022X.2016.1148523
        • Travassos D.C.
        • Fernandes D.
        • Massucato E.M.S.
        • Navarro C.M.
        • Bufalino A.
        Squamous cell carcinoma antigen as a prognostic marker and its correlation with clinicopathological features in head and neck squamous cell carcinoma: systematic review and meta-analysis.
        J Oral Pathol Med. 2018; 47: 3-10https://doi.org/10.1111/jop.12600
        • De Paz D.
        • Young C.K.
        • Chien H.T.
        • Tsao C.K.
        • Fok C.C.
        • Fan K.H.
        • Liao C.T.
        • Wang H.M.
        • Kang C.J.
        • Chang J.T.
        • Huang S.F.
        Prognostic roles of SCC antigen, CRP and CYFRA 21-1 in oral cavity squamous cell carcinoma.
        Anticancer Res. 2019; 39: 2025-2033https://doi.org/10.21873/anticanres.13313
        • Liu L.
        • Xie W.
        • Xue P.
        • Wei Z.
        • Liang X.
        • Chen N.
        Diagnostic accuracy and prognostic applications of CYFRA 21-1 in head and neck cancer: a systematic review and meta-analysis.
        PLoS One. 2019; 14e0216561https://doi.org/10.1371/journal.pone.0216561
        • Mikkelsen G.
        • Åsberg A.
        • Hultström M.E.
        • Aasarød K.
        • Hov G.G.
        Reference limits for chromogranin A, CYFRA 21-1, CA 125, CA 19-9 and carcinoembryonic antigen in patients with chronic kidney disease.
        Int J Biol Markers. 2017; 32: e461-e466https://doi.org/10.5301/ijbm.5000278
        • Oloomi M.
        • Moazzezy N.
        • Bouzari S.
        Comparing blood versus tissue-based biomarkers expression in breast cancer patients.
        Heliyon. 2020; 6e03728https://doi.org/10.1016/j.heliyon.2020.e03728
        • Duffy M.J.
        Clinical uses of tumor markers: a critical review.
        Crit Rev Clin Lab Sci. 2001; 38: 225-262https://doi.org/10.1080/20014091084218
        • Kanda M.
        • Koike M.
        • Shimizu D.
        • Tanaka C.
        • Kobayashi D.
        • Hattori N.
        • Hayashi M.
        • Omae K.
        • Yamada S.
        • Nakayama G.
        • Kodera Y.
        Optimized cutoff value of serum squamous cell carcinoma antigen concentration accurately predicts recurrence after curative resection of squamous cell carcinoma of the esophagus.
        Ann Surg Oncol. 2020; 27: 1233-1240https://doi.org/10.1245/s10434-019-07977-6
        • Charakorn C.
        • Thadanipon K.
        • Chaijindaratana S.
        • Rattanasiri S.
        • Numthavaj P.
        • Thakkinstian A.
        The association between serum squamous cell carcinoma antigen and recurrence and survival of patients with cervical squamous cell carcinoma: a systematic review and meta-analysis.
        Gynecol Oncol. 2018; 150: 190-200https://doi.org/10.1016/j.ygyno.2018.03.056
        • Nakamura H.
        • Nishimura T.
        History, molecular features, and clinical importance of conventional serum biomarkers in lung cancer.
        Surg Today. 2017; 47: 1037-1059https://doi.org/10.1007/s00595-017-1477-y
        • Kato H.
        • Torigoe T.
        Radioimmunoassay for tumor antigen of human cervical squamous cell carcinoma.
        Cancer. 1977; 40: 1621-1628https://doi.org/10.1002/1097-0142(197710)40:4<1621::AID-CNCR2820400435>3.0.CO;2-I
        • Wu Y.J.
        • Rheinwald J.G.
        A new small (40 kd) keratin filament protein made by some cultured human squamous cell carcinomas.
        Cell. 1981; 25: 627-635https://doi.org/10.1016/0092-8674(81)90170-7
        • Yin N.
        • Liu W.
        Clinical value of tumor marker index based on preoperative CYFRA 21-1 and SCC-ag in the evaluation of prognosis and treatment effectiveness in patients with esophageal squamous cell carcinoma.
        OncoTargets Ther. 2020; 13: 4135-4143https://doi.org/10.2147/OTT.S243038
        • Satyam A.
        • Singh P.
        • Sharma M.
        • Seth A.
        • Sharma A.
        CYFRA 21-1: a potential molecular marker for noninvasive differential diagnosis of urothelial carcinoma of bladder.
        Biomarkers. 2011; 16: 413-421https://doi.org/10.3109/1354750X.2011.582152
        • Cho H.Y.
        • Kyung M.S.
        CYFRA 21-1 and placental growth factor as screening markers for endometriosis.
        Med Sci Monit. 2019; 25: 1087-1092https://doi.org/10.12659/MSM.912787
        • Piao X.
        • Kong T.W.
        • Chang S.J.
        • Paek J.
        • Chun M.
        • Ryu H.S.
        Pretreatment serum CYFRA 21-1 level correlates significantly with survival of cervical cancer patients: a multivariate analysis of 506 cases.
        Gynecol Oncol. 2015; 138: 89-93https://doi.org/10.1016/j.ygyno.2015.04.012
        • Imai R.
        • Takenaka Y.
        • Yasui T.
        • Nakahara S.
        • Yamamoto Y.
        • Hanamoto A.
        • Takemoto N.
        • Fukusumi T.
        • Cho H.
        • Yamamoto M.
        • Inohara H.
        Prognostic significance of serum squamous cell carcinoma antigen in patients with head and neck cancer.
        Acta Otolaryngol. 2015; 135: 295-301
        • Huang S.F.
        • Wei F.C.
        • Liao C.T.
        • Wang H.M.
        • Lin C.Y.
        • Lo S.
        • Huang J.J.
        • Chen I.H.
        • Kang C.J.
        • Chien H.T.
        • Chen H.H.
        Risk stratification in oral cavity squamous cell carcinoma by preoperative CRP and SCC antigen levels.
        Ann Surg Oncol. 2012; 19: 3856-3864https://doi.org/10.1245/s10434-012-2392-5
        • Bruun L.
        • Savage C.
        • Cronin A.M.
        • Hugosson J.
        • Lilja H.
        • Christensson A.
        Increase in percent free prostate-specific antigen in men with chronic kidney disease.
        Nephrol Dial Transplant. 2009; 24: 1238-1241https://doi.org/10.1093/ndt/gfn632
        • Chen J.
        • Tao F.
        • Zhang B.
        • Chen Q.
        • Qiu Y.
        • Luo Q.
        • Gen Y.
        • Meng J.
        • Zhang J.
        • Lu H.
        Elevated squamous cell carcinoma antigen, cytokeratin 19 fragment, and carcinoembryonic antigen levels in diabetic nephropathy.
        Int J Endocrinol. 2017; 20175304391https://doi.org/10.1155/2017/5304391
      1. National Institute of Dental and Craniofacial Research. Oral cancer incidence (new cases) by age, race, and gender 2018. Updated July 2018. 〈https://www.nidcr.nih.gov/research/data-statistics/oral-cancer/incidence〉 [Accessibility verified February 12, 2022].